my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
11-11-2008: BTG plc announced it has granted worldwide rights to Onyx Pharmaceuticals, Inc. to develop and commercialise BTG’s novel anticancer compound, BGC 945. Under the terms of the agreement, BTG will receive an upfront payment of $13m and has the potential to receive development milestone payments of up to $72m plus additional payments of up to $235m relating to product approval and achievement of commercial milestones. BTG will also receive a royalty on any future sales worldwide.
BTG has progressed BGC 945 into late-stage preclinical development in collaboration with The Institute of Cancer Research (ICR) where the compound was discovered. BTG will share approximately 10% of the upfront and milestone revenues it receives relating to BGC 945 with ICR plus a pass-through royalty.
BGC 945 is a compound that inhibits thymidylate synthase (TS), an enzyme involved in cell growth and division. However, unlike traditional TS inhibitors, BGC 945 enters tumour cells via the alpha-folate receptor, which is over-expressed in certain tumour types, including ovarian, lung, endometrial and mesothelioma cells, but has a restricted expression profile in normal tissues.
Watchlist
This is where you can add this news to your personal favourites
S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors
S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc. announced the expansion of their development collaboration and option and license commercialization agreement for S*BIO’s novel JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively. The expanded agreement builds u ... more
Bayer and Onyx Initiate Phase III Trial of Nexavar in Patients with Non-Responsive Thyroid Cancer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that the companies have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differe ... more
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that their first cooperative group-sponsored randomized Phase II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar® (sorafenib) tablets in combinati ... more
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. Our lead product is Nexavar® (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis (the f ... more
BTG plc: Completion of the Acquisition of Protherics PLC
BTG plc announced that all the conditions to its recommended offer for Protherics PLC have been satisfied and the Acquisition has therefore been completed. Accordingly, 104,044,710 new BTG ordinary shares of 10 pence each issued in connection with the Acquisition were admitted to the Offici ... more
BTG licenses novel anticancer compound to Onyx Pharmaceuticals
BTG plc announced it has granted worldwide rights to Onyx Pharmaceuticals, Inc. to develop and commercialise BTG’s novel anticancer compound, BGC 945. Under the terms of the agreement, BTG will receive an upfront payment of $13m and has the potential to receive development milestone payment ... more
BTG plc: Tolerx initiates dosing of otelixizumab in a phase III clinical trial in type 1 diabetes
BTG plc notes the announcement by Tolerx, Inc. that it has initiated a pivotal phase III clinical trial of otelixizumab (TRX4) in patients with new onset type 1 diabetes. Initiation of the DEFEND (Durable Response Therapy Evaluation For Early or New Onset Type 1 Diabetes) triggers a milesto ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
